|

CD19 CAR-T-cells Clinical Trials

7 actively recruiting trials

No change since May 2026

Also known as: CD19 CAR-T cells injection

Pipeline

Phase 1: 4Phase 1/2: 2Phase 2/3: 1

Top Sponsors

  • National University of Malaysia2
  • University Hospital Heidelberg1
  • The Children's Hospital of Zhejiang University School of Medicine1
  • Chongqing Precision Biotech Co., Ltd1
  • Belarusian Research Center for Pediatric Oncology, Hematology and Immunology1

Indications

  • Lupus4
  • Cancer3
  • Systemic Lupus Erythematosus2
  • Lupus Nephritis (LN)1
  • Systemic Lupus Erythematous (SLE)1

Other7 trials

Anti-CD19 Chimeric Antigen Receptor T Cells for Refractory Systemic Lupus Erythematosus
Phase 1/2
Autologous CD19 Car T-Cell Therapy For Severe Refractory Systemic Lupus Erythematosus (SLE)
Phase 1
Intravenous Autologous CD19 CAR-T Cells for R/R B-ALL
Phase 2/3
Pilot CAR-T Cells Therapy for Children/Young Adults With CD19+ R/R Leukemia/Lymphoma
Phase 1
Study of Ultra-Fast CD19 CAR-T Therapy for Refractory SLE
Phase 1
Study of Ultra-Fast CD19 CAR-T Therapy for Refractory SLE
Phase 1
Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR
Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.